TY - JOUR T1 - Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer JF - Anticancer Research JO - Anticancer Res SP - 5859 LP - 5866 DO - 10.21873/anticanres.12928 VL - 38 IS - 10 AU - KEIJI SUGIYAMA AU - YUKIYA NARITA AU - SEIICHIRO MITANI AU - KAZUNORI HONDA AU - TOSHIKI MASUISHI AU - HIROYA TANIGUCHI AU - SHIGENORI KADOWAKI AU - TAKASHI URA AU - MASASHI ANDO AU - MASAHIRO TAJIKA AU - KEI MURO Y1 - 2018/10/01 UR - http://ar.iiarjournals.org/content/38/10/5859.abstract N2 - Aim: To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy. Patients and Methods: Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a ≥10% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS). Results: Of 118 patients, 89% had baseline sarcopenia and 31% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities. Conclusion: Muscle loss during chemotherapy negatively affected survival among patients with mGC. ER -